X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4190) 4190
Book Review (1390) 1390
Publication (215) 215
Magazine Article (24) 24
Book Chapter (21) 21
Conference Proceeding (8) 8
Trade Publication Article (7) 7
Newsletter (6) 6
Newspaper Article (4) 4
Book / eBook (1) 1
Dissertation (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3338) 3338
index medicus (3283) 3283
dabigatran (3241) 3241
warfarin (2049) 2049
anticoagulants - therapeutic use (1769) 1769
anticoagulants (1754) 1754
rivaroxaban (1658) 1658
atrial fibrillation (1442) 1442
male (1286) 1286
female (1194) 1194
administration, oral (1152) 1152
aged (1141) 1141
stroke (1139) 1139
atrial fibrillation - drug therapy (1126) 1126
apixaban (1025) 1025
anticoagulants - adverse effects (1004) 1004
stroke - prevention & control (956) 956
dabigatran etexilate (921) 921
anticoagulants - administration & dosage (866) 866
benzimidazoles - therapeutic use (855) 855
atrial fibrillation - complications (806) 806
cardiac & cardiovascular systems (800) 800
beta-alanine - analogs & derivatives (793) 793
prevention (786) 786
middle aged (754) 754
hemorrhage - chemically induced (748) 748
atrial-fibrillation (738) 738
warfarin - therapeutic use (727) 727
hematology (718) 718
peripheral vascular disease (701) 701
venous thromboembolism (675) 675
risk factors (661) 661
pharmacology & pharmacy (643) 643
treatment outcome (633) 633
thromboembolism (630) 630
aged, 80 and over (579) 579
beta-alanine - therapeutic use (563) 563
management (530) 530
stroke prevention (526) 526
dabigatran - therapeutic use (525) 525
pyridones - therapeutic use (523) 523
pyrazoles - therapeutic use (521) 521
anticoagulation (518) 518
risk (517) 517
medicine, general & internal (514) 514
antithrombins - therapeutic use (511) 511
stroke - etiology (504) 504
thrombin (484) 484
safety (482) 482
therapy (480) 480
abridged index medicus (455) 455
benzimidazoles - adverse effects (443) 443
cardiac arrhythmia (438) 438
medicine & public health (432) 432
oral anticoagulants (429) 429
pyridines - therapeutic use (425) 425
analysis (418) 418
drug therapy (410) 410
direct thrombin inhibitor (407) 407
care and treatment (398) 398
thiophenes - therapeutic use (389) 389
morpholines - therapeutic use (388) 388
bleeding (385) 385
hemorrhage (372) 372
warfarin - adverse effects (362) 362
cardiology (354) 354
vitamin k - antagonists & inhibitors (337) 337
benzimidazoles - administration & dosage (336) 336
antithrombins - adverse effects (334) 334
dabigatran - adverse effects (334) 334
thrombosis (323) 323
blood coagulation - drug effects (316) 316
beta-alanine - adverse effects (314) 314
patients (306) 306
retrospective studies (304) 304
rivaroxaban - therapeutic use (303) 303
efficacy (302) 302
venous thromboembolism - prevention & control (302) 302
adult (298) 298
thromboembolism - prevention & control (294) 294
edoxaban (291) 291
dosage and administration (289) 289
antithrombotic therapy (282) 282
internal medicine (279) 279
factor xa inhibitors (278) 278
pharmacokinetics (272) 272
venous thromboembolism - drug therapy (272) 272
mortality (270) 270
risk assessment (268) 268
surgery (267) 267
metaanalysis (261) 261
randomized controlled trials as topic (259) 259
factor xa inhibitor (256) 256
double-blind (255) 255
warfarin - administration & dosage (253) 253
anticoagulants - pharmacology (248) 248
reversal (248) 248
direct oral anticoagulants (245) 245
cardiovascular (240) 240
clinical trials (240) 240
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3913) 3913
German (91) 91
Spanish (70) 70
French (62) 62
Russian (19) 19
Japanese (12) 12
Czech (9) 9
Hungarian (9) 9
Swedish (9) 9
Danish (8) 8
Italian (8) 8
Portuguese (5) 5
Finnish (4) 4
Polish (4) 4
Dutch (3) 3
Turkish (2) 2
Chinese (1) 1
Korean (1) 1
Norwegian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2015, Volume 128, Issue 12, pp. 1300 - 1305.e2
Journal Article
Circulation, ISSN 0009-7322, 02/2013, Volume 127, Issue 5, pp. 634 - 640
Journal Article
Stroke, ISSN 0039-2499, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies | Index Medicus
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 60, Issue 8, pp. 738 - 746
Objectives This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative... 
Cardiovascular | Internal Medicine | indirect comparisons | dabigatran | atrial fibrillation | rivaroxaban | apixaban | stroke prevention | NETWORK | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | METAANALYSIS | RISK | THERAPY | WARFARIN | ASSOCIATION | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Dabigatran | Pyridones - administration & dosage | Rivaroxaban | Clinical Trials, Phase III as Topic | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Female | Benzimidazoles - adverse effects | Odds Ratio | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Stroke - etiology | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Stroke (Disease) | Usage | Analysis | Atrial fibrillation | Anticoagulants (Medicine) | Universities and colleges | Cardiology | Anticoagulants | Cardiac arrhythmia | Stroke | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 03/2017, Volume 135, Issue 11, pp. 1024 - 1035
BACKGROUND:Intravenous rt-PA (recombinant tissue-type plasminogen activator) is effective in improving outcomes in ischemic stroke; however, there are few data... 
thrombolysis, therapeutic | anticoagulant agents | intracranial hemorrhages | stroke, acute | CARDIAC & CARDIOVASCULAR SYSTEMS | DABIGATRAN ANTICOAGULATION | PERFORMANCE | GUIDELINES | RISK SCORE | HEALTH-CARE PROFESSIONALS | INTRACRANIAL HEMORRHAGE | therapeutic | EARLY MANAGEMENT | WARFARIN | HEART-ASSOCIATION | thrombolysis | PERIPHERAL VASCULAR DISEASE | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Tissue Plasminogen Activator - metabolism | Humans | Male | Tissue Plasminogen Activator - therapeutic use | Recombinant Proteins - biosynthesis | Tissue Plasminogen Activator - genetics | Dabigatran - therapeutic use | Warfarin - therapeutic use | Recombinant Proteins - isolation & purification | Time Factors | Fibrinolytic Agents - therapeutic use | Hemorrhage - etiology | Aged, 80 and over | Female | Registries | Retrospective Studies | Stroke - mortality | Rivaroxaban - therapeutic use | Hospital Mortality | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Stroke - drug therapy | International Normalized Ratio | Administration, Intravenous | Aged | Pyridones - therapeutic use | Stroke (Disease) | Treatment outcome | Care and treatment | Usage | Tissue plasminogen activator | Analysis | Dosage and administration | Thrombolytic therapy | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 03/2015, Volume 131, Issue 11, pp. 972 - 979
BACKGROUND—Dabigatran and rivaroxaban are new oral anticoagulants that are eliminated through the kidneys. Their use in dialysis patients is discouraged... 
Rivaroxaban | Warfarin | Dialysis | Dabigatran | Atrial fibrillation | dialysis | atrial fibrillation | CARDIAC & CARDIOVASCULAR SYSTEMS | dabigatran | RISK | PERIPHERAL VASCULAR DISEASE | rivaroxaban | warfarin | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | beta-Alanine - pharmacokinetics | Hospitalization - statistics & numerical data | Warfarin - adverse effects | Male | Risk | Drug Utilization | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Practice Patterns, Physicians' - statistics & numerical data | Kidney - metabolism | Matched-Pair Analysis | Aged, 80 and over | Female | Retrospective Studies | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Databases, Factual | beta-Alanine - adverse effects | Kidney - drug effects | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Benzimidazoles - pharmacokinetics | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Kidney Failure, Chronic - metabolism | Warfarin - pharmacokinetics | Practice Patterns, Physicians' - trends | Atrial Fibrillation - metabolism | Thiophenes - pharmacokinetics | Stroke - etiology | Kidney Failure, Chronic - complications | Poisson Distribution | Aged | Anticoagulants - pharmacokinetics | Hemorrhage - chemically induced | Morpholines - pharmacokinetics | Renal Dialysis | Index Medicus | Abridged Index Medicus
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e531S - e575S
Background: The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is... 
DIRECT-CURRENT CARDIOVERSION | STROKE PREVENTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | ORAL ANTICOAGULANT-THERAPY | RISK STRATIFICATION SCHEMES | MAJOR VASCULAR EVENTS | PULMONARY-VEIN ABLATION | ACUTE CORONARY SYNDROME | ECHOCARDIOGRAPHY-GUIDED CARDIOVERSION | ANTIARRHYTHMIC-DRUG THERAPY | CRITICAL CARE MEDICINE | Ticlopidine - therapeutic use | Humans | Electric Countershock | Hemorrhage - prevention & control | Dabigatran | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Stroke - prevention & control | beta-Alanine - adverse effects | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Atrial Fibrillation - blood | International Normalized Ratio | Stroke - blood | Atrial Flutter - complications | Atrial Flutter - drug therapy | Hemorrhage - chemically induced | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article